ArticleScientific reports2026
Surrogate virus neutralization test as a scalable and reliable tool for immune surveillance in booster-vaccinated populations.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
With waning vaccine-induced immunity and the continued emergence of immune-evasive SARS-CoV-2 variants, booster vaccination has become essential for sustaining population-level protection. However, scalable and reliable serological tools for monitoring post-booster humoral immunity across different vaccine platforms remain insufficiently evaluated. We conducted a cross-sectional study and a booster cohort study to systematically compare the performance and concordance of surrogate virus neutralization test (sVNT), pseudovirus neutralization test (pVNT), and binding IgG antibody assays. In the cross-sectional analysis, serum samples from 259 individuals collected 1-2 months after a third dose of inactivated vaccine were used to compare sVNT and pVNT. In the booster cohort, paired sera from 288 participants receiving a fourth dose with different vaccine platforms were analyzed to evaluate the relationship between sVNT and IgG responses. Correlation and agreement were assessed using Spearman correlation and Bland-Altman analyses. In the cross-sectional study, sVNT showed strong concordance with pVNT, demonstrated by a very high correlation (r = 0.97) and good agreement in Bland-Altman analysis. In the booster cohort study, IgG antibody levels correlated strongly with sVNT overall (r = 0.91). The correlation strength remained highly consistent across different vaccine platforms, with no statistically significant differences observed. Collectively, these findings demonstrate that sVNT closely reflects functional neutralizing activity, supporting its utility for large-scale immune monitoring. sVNT offers an optimal balance of analytical performance and scalability for high-throughput monitoring without requiring cell-based assays. Consequently, we propose a tiered immune monitoring strategy: utilizing sVNT for broad population-level surveillance and reserving pVNT for targeted, precise functional assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.